New developments in CRISPR gene editing technology have opened the door to potential cures for 89% of known disease-causing genetic variations in DNA. Advancements have also focused on using CRISPR enzymes to fight viruses in human cells. Additionally, positive sales figures for treatments from Novartis and Spark Therapeutics have injected optimism into the market and bolstered CRISPR’s case for commercial viability in the near-term.

To read this Market Insight, you’ll need to  sign in

If you don’t have a subscription,  get in touch  for a free trial.